John Bencich
2019
In 2019, John Bencich earned a total compensation of $570.5K as Executive Vice President and Chief Financial Officer and Chief Operating Officer at OncoGenex Pharmaceuticals, a 18% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $121,590 |
---|---|
Option Awards | $43,657 |
Salary | $405,300 |
Total | $570,547 |
Bencich received $405.3K in salary, accounting for 71% of the total pay in 2019.
Bencich also received $121.6K in non-equity incentive plan and $43.7K in option awards.
Rankings
In 2019, John Bencich's compensation ranked 11,362nd out of 13,971 executives tracked by ExecPay. In other words, Bencich earned more than 18.7% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 11,362 out of 13,971 | 19th |
Division Manufacturing | 4,607 out of 5,701 | 19th |
Major group Chemicals And Allied Products | 1,814 out of 2,200 | 18th |
Industry group Drugs | 1,561 out of 1,886 | 17th |
Industry In Vitro and In Vivo Diagnostic Substances | 55 out of 77 | 29th |
Source: SEC filing on April 2, 2020.
Bencich's colleagues
We found three more compensation records of executives who worked with John Bencich at OncoGenex Pharmaceuticals in 2019.
News
OncoGenex Pharmaceuticals CEO John Bencich's 2022 pay slips 7% to $1.5M
April 28, 2023
OncoGenex Pharmaceuticals CEO John Bencich's 2021 pay jumps 82% to $1.6M
April 21, 2022
OncoGenex Pharmaceuticals CEO Richard Stewart's 2020 pay jumps 30% to $1M
March 30, 2021
OncoGenex Pharmaceuticals CEO Richard Stewart's 2019 pay falls 27% to $797K
April 2, 2020
OncoGenex Pharmaceuticals CEO Richard Stewart's 2018 pay jumps 423% to $1.1M
March 28, 2019